ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Mallinckrodt Completes Acquisition of Ocera Therapeutics, OCR-002
americanpharmaceuticalreview
December 12, 2017Mallinckrodt has closed the acquisition of Ocera Therapeutics, a clinical-phase biopharmaceutical company focused on the development and commercialization of novel therapeutic drugs for orphans and other serious liver diseases that have not been met -
Mallinckrodt to Acquire Ocera Therapeutics, OCR-002
americanpharmaceuticacreview
November 03, 2017The FDA granted OCR-002 its Orphan Drug Designation, and the resulting seven years' exclusivity would be applied upon first approval of the drug.
Pharma Sources Insight January 2025
